Fungal infections in patients undergoing bone marrow transplantation: An approach to a rational management protocol

Bone Marrow Transplantation

Volumn 18, Issue SUPPL. 2, 1996, Pages 97-106

  Castagnola, E ^a   Bucci, B ^b   Montinaro, E ^a   Viscoli, C ^b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; COLONY STIMULATING FACTOR 1; CYCLODEXTRIN; DEOXYCHOLIC ACID; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTRALIPID; ITRACONAZOLE; LIPID; PRADIMICIN A; PYRROLE DERIVATIVE;

ANAPHYLAXIS; ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; BRONCHOSPASM; CANDIDA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG USE; FEVER; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; MORBIDITY; MORTALITY; MYCOSIS; NEURITIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RIGOR; THROMBOCYTOPENIA; TREMOR; UREMIA; VOMITING;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; PRACTICE GUIDELINES;

EID: 0029824849     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Viscoli C, Castagnola E. Factors predisposing cancer patients to infection. In: Klastersky J (ed): Infectious complications of cancer. Klauwer Academic Publisher 1995: 1-30
2. Viscoli C., Boni L., Etzioni R., Seidel K., Anasetti C. Infecions in Recipients of Bone Marrow Transplant (Bmt) From Unrelated Donors. 8th International Symposium on Infections in the Immunocompromised Host. 19-22.06.1994 Davos Switzerland, Abs. No 39.
3. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantation: comparison on incidence in related and unrelated donor transplant recipients. Blood 1995; 86: 3979-3986.
4. Kunin CM. 1993 Resistance to antimicrobial drugs - A worldwide calamity. Ann Intern Med ; 118: 557-561.
5. Zaia JA, Forman SJ Cytomegalovirus infection in the bone marrow transpant recipient. 1995. On Infection in Transplantation. Rubin RH. Editor. Infectious Disease Clinics of North America. Sounders Publ. 9:4 879-900.
6. Walsh TJ, Lyman CA. 1995 New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. On Infectious Complications of Cancer. J. Klastersky Editor. Kluwer Academic Publ.
7. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8
8. Van Burik JH, Bowden RA. Standard antifungal treatment, including role of alternative modalities to administer amphotericin B. Bailliere's Clinical Infectious Diseases; 1995; 2: 89-109.
9. Van't Wout JW. Therapeutic indications for new triazoles and potential emergence of resistance. Bailliere's Clinical Infectious Diseases; 1995; 2: 111-126.
10. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329.
11. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Intern 1991; 40: 302-308
12. Todeschini G, Murari C, Bonesi R, Pizzolo G, Arnaddi G, Ambrosetti A, et al. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1993; 12:614-618.
13. Bennett JE. 1990 Antifungal agents. In Principle and Practice of Infectious Diseases. Mandell, Douglas, Bennet Editor.Churchill Livigstone Publ.
14. Graybill JR. Lipid formulations of amphotericin B: does the emperor need new clothes? Ann Intern Med 1996; 124:921-923.
15. Moreau P, Milpied N, Fayette N, et al. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin b in neutropenic patients. J Antimicrob Chemother 1992; 30: 535-541.
16. Trissel LA. Amphotericin does not mix with fat emulsion Am J Health Syst Pharm 1995; 52:1463-1464.
17. Francis P, Walsh TJ. 1992. The evolving role of flucytosine in immunocompromised patients: new insight into safety, pharmacokinetics, and antifungal therapy. Rev. Infect. Dis 15:1003-1018.
18. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
19. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden R. 1995. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J.I.D. 171:1545-1552.
20. Ninane J. and a multicentre Study Group (Participants ... C. Viscoli ...) 1994. A multicentre study of fluconazole versus oral polynes in the prevention of fungal infection in children with hematological or oncological malignancies. Eur. J. Clin. Microbiol. Infect. Dis. 13(4):330-337.
21. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H et al Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
22. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in granulocytopenic patients with acute leukemia: fluconazole compared with oral Amphotericin B Ann Interm Med 1994; 120: 913-918
23. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277
24. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infection with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-1849
25. Fan-Havard P, Capano D, Smith SM, et al. 1991. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob. Agents Chemother. 35:2302-2305.
26. Sayer HG, Longton G, Bowden R, Pepe M, Storb R. 1994. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 84(4): 1328-32.
27. Karp JE, Burch P, Mertz MG An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 1988; 85: 203-209.
28. Perfect JR, Klotman ME, Gilbert CC, Krawford DD, Rosner GL, Wright KA, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165: 891-897
29. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, DeBeule K. 1989, Antifungal prophylaxis with itraconazole in prolonged neutropcnia: correlation with plasma levels. Mycoses 32(suppl 1):103-108.
30. Hiemenz JE, Walsh TJ. Lipid formulations of amphotericin B: progress and future directions. Clin Infect Dis 1996; 22 (suppl 2): S133-S144.
31. Rex JH, Bennet JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RJ, Scheld Wm, Karchmer AW, Dine AP, Levenstein MJ, Webb CD. 1994. A randomized trial comparing fluconazole with amphotericine B for the treatment of candidemia in patients without neutropenia. New Engl. J. Med. 331(20)1325-30.
32. Rex JH. 1996. Editorial response: Catheters and candidemia. CID 22(3):467-470.
33. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-11
34. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668-72
35. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multiventre, prospective and randomised clinical trial. Eur J Cancer 1996; 32:814-820.
36. Powderly WG, Saag GA, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 793-798.
37. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995; 39: 1907-1912
38. Lecciones GA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992; 14: 875-883.
39. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12: 1147-1201.
40. Herbecht R, Cordonnier C. 1995. Impact of cytokines and growth factors in the antifungal armamentatium. on Invasive Fungal Infections in Cancer Patients. F. Meunier Editor. Baillière's Clinical Infectious Disease 2(1):141-55.
41. Strauss RG. Therapeutic granulocyte transfusions in 1993. Blood 1993; 81: 1675-1678.